Moderna Inc is partnering with contract drugmaker Catalent Inc for filling and packaging millions of doses of its experimental coronavirus vaccine to be supplied in the United States.
The vaccine, among the first to be tested in humans in the United States, was found to produce protective antibodies in a small group of healthy volunteers. The company plans to begin late-stage trials in July.
Under the deal, Catalent will provide manufacturing services for an initial 100 million doses starting in the third quarter at its facility in Bloomington, Indiana.
It will also provide other packaging and labeling, storage and distribution services at its facilities in Philadelphia, Pennsylvania.